Now, it’s worth noting Stock Advisor ’s total average return is 1,045 % — a market-crushing outperformance compared to 178 % for the S&P 500. Don’t miss out on the latest top 10 list ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since 2022 is largely due to its coronavirus portfolio. Terrible News for Pfizer ...

Pfizer's dismal stock performance in recent years underscores the challenges the big drugmaker faces. The company's COVID-19 product sales have declined sharply from their peak at the height of ...

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average dividend payer in the S&P 500.If it can't maintain its payout-raising streak ...

Detailed price information for Novartis Ag ADR (NVS-N) from The Globe and Mail including charting and trades.

Study Design: This interventional study is randomized and follows a parallel assignment model. It is double-blind, meaning neither participants nor the care providers, investigators, or outcome ...

Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee ...